Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

579 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3.
Aguado JM, Gomez-Sanchez MA, Lumbreras C, Delgado J, Lizasoain M, Otero JR, Rufilanchas JJ, Noriega AR. Aguado JM, et al. Antimicrob Agents Chemother. 1995 Jul;39(7):1643-5. doi: 10.1128/AAC.39.7.1643. Antimicrob Agents Chemother. 1995. PMID: 7492123 Free PMC article. Clinical Trial.
Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies.
Lumbreras C, Otero JR, Herrero JA, Gomez R, Lizasoain M, Aguado JM, Colina F, Garcia I, Moreno E, Noriega AR. Lumbreras C, et al. Among authors: aguado jm. Antimicrob Agents Chemother. 1993 Nov;37(11):2490-2. doi: 10.1128/AAC.37.11.2490. Antimicrob Agents Chemother. 1993. PMID: 8285641 Free PMC article.
Prophylaxis of cytomegalovirus disease with ganciclovir or anti-CMV immunoglobulin in renal transplant recipients who receive antilymphocytic antibodies as induction therapy.
Morales E, Andrés A, González E, Herrero JC, Muñoz MA, Ortiz M, Espejo B, Lumbreras C, Morales JM, Aguado JM. Morales E, et al. Among authors: aguado jm. Transplant Proc. 2002 Feb;34(1):73-4. doi: 10.1016/s0041-1345(01)02671-9. Transplant Proc. 2002. PMID: 11959191 No abstract available.
Is double renal transplantation a risk factor for cytomegalovirus disease?
Moreno-Cuerda VJ, Aguado JM, Morales M, Andrés A, Morales JM, López-Medrano F, San Juan R, Lumbreras C. Moreno-Cuerda VJ, et al. Among authors: aguado jm. Transplant Proc. 2005 Nov;37(9):3764-5. doi: 10.1016/j.transproceed.2005.09.180. Transplant Proc. 2005. PMID: 16386531
Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients.
Díaz-Pedroche C, Lumbreras C, Del Valle P, San Juan R, Hernando S, Folgueira D, Andrés A, Delgado J, Meneu JC, Morales JM, Moreno E, Aguado JM. Díaz-Pedroche C, et al. Among authors: aguado jm. Transplant Proc. 2005 Nov;37(9):3766-7. doi: 10.1016/j.transproceed.2005.10.075. Transplant Proc. 2005. PMID: 16386532 Clinical Trial.
Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients.
Díaz-Pedroche C, Lumbreras C, San Juan R, Folgueira D, Andrés A, Delgado J, Meneu JC, Morales JM, Moreno-Elola A, Hernando S, Moreno-González E, Aguado JM. Díaz-Pedroche C, et al. Among authors: aguado jm. Transplantation. 2006 Jul 15;82(1):30-5. doi: 10.1097/01.tp.0000225830.76907.d0. Transplantation. 2006. PMID: 16861938 Clinical Trial.
579 results